Avacta will tap into Tempus' real-world data and machine learning abilities to develop drugs with its fibroblast activation protein (FAP)-based platform.
The recommendation was based on results from two Phase III trials showing that Tevimbra plus chemo improved overall survival over chemo alone.
The LRRK2 Investigative Therapeutics Exchange aims to advance basic sciences and support development of new drugs and LRRK2-specific biomarkers.